Updated:
Anika Therapeutics
Anika Therapeutics operates from Bedford, Massachusetts, with additional offices in Indiana and Padova, Italy.
Anika Therapeutics
Anika Therapeutics operates from Bedford, Massachusetts, with additional offices in Indiana and Padova, Italy. The company was founded as a hyaluronic-acid specialist and has remained tethered to that molecule across three decades, a focus that sets it apart in an orthopedic sector where most competitors diversify across biomaterials. Anika's HA platform yields three regenerative products — Integrity (a porous rotator-cuff scaffold), Hyalofast (a single-stage cartilage-repair scaffold), and Tactoset (an injectable bone substitute) — alongside its viscosupplementation injections for osteoarthritis pain. The company distributes its OA pain-management injections Orthovisc and Monovisc exclusively through J&J MedTech in the United States, while its next-generation dual-action injection Cingal — combining HA with a fast-acting corticosteroid — is sold across more than 45 countries outside the U.S. through an international distributor network. Anika packages its pipeline around distinct clinical-stage categories: tendon and cartilage repair, bone augmentation, and non-opioid pain management. The company emphasizes that its regenerative scaffolds function as off-the-shelf surgical solutions — Hyalofast, for instance, requires no cell harvesting and can be implanted in a single procedure, echoing a broader industry push toward simplified orthobiologics workflows. Anika maintains its research-and-manufacturing footprint in Bedford and Padova, while its Warsaw, Indiana office supports U.S. customer service. The firm has invested in a dedicated direct-sales team to commercialize Integrity, moving away from the distribution-only model that characterizes its legacy viscosupplement line. The leadership team has not been publicly enumerated on the company website, and Anika's headcount is not disclosed. The firm's most recent product brochures and patient testimonials emphasize rotator-cuff repair outcomes, signaling a commercial priority shift toward the surgical regenerative segment. Structurally, Anika is a publicly traded pure-play HA medtech company — a rare concentration in orthopedic R&D, where most publicly listed competitors maintain broader biomaterial or anatomic portfolios. The J&J MedTech channel for its U.S. pain-management injections creates a split commercial identity: a distributor-dependent cash-generating legacy business alongside a nascent, direct-sales regenerative franchise. The Padova-based European operation handles international distribution and regenerative-product support, giving Anika a dual-continent operational base that distinguishes its manufacturing architecture from U.S.-only orthopedic peers.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Bedford
Corporate office
32 Wiggins Avenue, Bedford, MA 01730, USA
Additional offices
Warsaw, IN, USA · Padova, Italy
Sector focus
Frequently asked questions
What is Anika Therapeutics' core technology platform?
Anika's entire product portfolio is built around hyaluronic acid (HA), the naturally occurring molecule that lubricates joints. The company has refined proprietary HA formulations over three decades into three distinct application categories: viscosupplementation injections for osteoarthritis pain (Monovisc, Orthovisc, Cingal), regenerative scaffolds for soft-tissue and cartilage repair (Integrity, Hyalofast), and an injectable bone substitute (Tactoset). Cingal combines HA with a fast-acting corticosteroid for dual-action pain relief — a formulation available in over 45 countries outside the U.S.
How does Anika's U.S. commercial model split between distribution partners and a direct salesforce?
Anika relies on J&J MedTech as the exclusive U.S. distributor for its viscosupplementation injections Orthovisc and Monovisc. For the regenerative portfolio — led by the Integrity rotator-cuff scaffold — the company has built a direct sales team. Outside the U.S., Anika distributes most products through a network of global commercial partners, with Cingal as the flagship international offering.
Which clinical indications does Anika currently address with its regenerative products?
The Integrity implant targets rotator-cuff and other tendon repair procedures, functioning as a porous HA-based scaffold that supports tissue regeneration. Hyalofast is an off-the-shelf, single-stage scaffold for cartilage repair designed to promote hyaline-like cartilage regeneration. Tactoset addresses insufficiency fractures and augments hardware such as suture anchors by providing an HA-enhanced injectable bone substitute that sets in situ.
Where are Anika's manufacturing and R&D operations located?
Anika's headquarters and primary operations are in Bedford, Massachusetts. The firm maintains an additional U.S. office in Warsaw, Indiana, focused on customer service. Its European base is in Padova, Italy, managed through Anika Therapeutics S.r.l., which handles international sales support for products including Hyalofast and Cingal. This dual-continent setup supports both U.S. manufacturing and European distribution.
In which countries is Cingal currently available?
Cingal is not sold in the United States. It is available in over 45 countries outside the U.S. through Anika's international distributor network, with the Padova, Italy office serving as the commercial-support hub for global partners. The specific country list is not published on Anika's website; contact information for international distribution partners is handled through the company's Bedford and Padova offices.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: